<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547154</url>
  </required_header>
  <id_info>
    <org_study_id>C98026</org_study_id>
    <secondary_id>MK-4031-001</secondary_id>
    <secondary_id>C98-026</secondary_id>
    <nct_id>NCT03547154</nct_id>
  </id_info>
  <brief_title>Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)</brief_title>
  <official_title>A RANDOMIZED PHASE 2/3 TRIAL OF SCH 54031 PEG12000 INTERFERON ALFA-2b (PEG INTRON, SCH 54031) VS. INTRON A (SCH 30500) IN SUBJECTS WITH NEWLY DIAGNOSED CML (PROTOCOL NOS. C/I98-026)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the efficacy of polyethylene glycol (PEG;
      pegylated) interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in
      the treatment of participants with newly diagnosed CML.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 22, 1998</start_date>
  <completion_date type="Actual">February 20, 2001</completion_date>
  <primary_completion_date type="Actual">February 20, 2001</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Cytogenetic Responses to PEG Intron and INTRON A at 12 Months</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Cytogenetic response (CR) was defined by the degree of suppression of Philadelphia chromosome (Ph^1) achieved during study treatment. For all participants continuing treatment after study conclusion, cytogenetic assessments were conducted locally as per standard of care. Determination of CR at 12 months were based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH^1-positive cells during study treatment. Protocol-defined CR criteria were Complete Response (0%), Partial Response (1-34%), Minor Response (35-90%), or No Response (&gt;90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cytogenetic Response (CR) to PEG Intron and Intron A at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Cytogenetic response (CR) at 6 months, as at 12 months, was defined by the degree of suppression of Philadelphia chromosome (Ph^1) achieved during study treatment. The determination of CR at 6 months was based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH^1-positive cells during study treatment. Protocol-defined CR criteria were Complete (0%), Partial (1-34%), Minor (35-90%), or No Response (&gt;90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematologic Responses to PEG Intron and Intron A at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Hematologic response at 6 months was assessed, while the hematologic response was measured at 3, 6, 9 and 12 months during the first year of study treatment. To be considered a hematologic responder a participant must have met all of the following criteria for a minimum of 28 days: WBC count &lt;10,000/μL; platelet count &lt;450,000/L; normal differential count in peripheral blood (manual differential count); no palpable spleen. Participants achieving a complete hematologic response at 3 months had the cytogenetic response evaluated at 3 months as well. Participants who achieved a complete hematologic response by 6 months continued treatment for another 6 months. Participants who failed to achieve a complete hematologic response after 6 months of treatment were considered treatment failures, and further treatment for this group was at the discretion of the treating physician. Participants may have continued to receive their assigned study medication for an additional 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival</measure>
    <time_frame>Up to 2 years (24 months), and beyond</time_frame>
    <description>Participants were followed for survival; those who did not achieve a major cytogenetic response were discontinued from the study. For participants who completed 1 year of study treatment and continued to Year 2 and beyond, survival and disease progression every 3 months were assessed, and serious adverse events (SAEs) were reported. Participants were followed until resolution of any drug-related nonserious adverse event, and any SAE occurring while on the study or within 30 days of last dose of study drug. Participant death during survival follow-up was reported to the drug safety unit of the Sponsor. Each participant (whether discontinued or still on treatment) was followed every 3 months for survival and disease progression information. Overall survival was analyzed using the log-rank statistic, and the hazard ratio (HR) and 95% confidence interval (CI) for the HR were obtained using Cox's proportional hazards model.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">344</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Pegylated interferon alfa-2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received pegylated interferon alfa-2b (PEG Intron) at a dose of 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the white blood cell (WBC) count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon alfa-2b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received interferon alfa-2b (Intron^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegylated interferon alfa-2b</intervention_name>
    <description>Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg</description>
    <arm_group_label>Pegylated interferon alfa-2b</arm_group_label>
    <other_name>PEG Intron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interferon alfa-2b</intervention_name>
    <description>Daily SC injection of interferon alfa-2b, 5 MIU/m^2</description>
    <arm_group_label>Interferon alfa-2b</arm_group_label>
    <other_name>INTRON^® A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Has chronic phase CML diagnosed within 3 months prior to study enrollment

          -  Has chronic phase CML positive for Ph^1 as confirmed by cytogenetic studies, performed
             by a central laboratory

          -  Has platelet count &gt;/= 50,000/microl

          -  Has hemoglobin &gt;/= 9.0 g/dL

          -  Has WBC count &gt;/=2000/microl but &lt;/= 50,000/microl

          -  Has adequate hepatic and renal function, as defined by the following parameters
             obtained within 14 days prior to initiation of study treatment

               -  serum glutamic oxaloacetic transaminase (SGOT) &lt;2 times upper limit of laboratory
                  normal (ULN)

               -  serum glutamic pyruvic transaminase SGPT &lt;2 times upper ULN

               -  serum bilirubin &lt;2 times ULN

               -  serum creatinine &lt;2.0 mg/dL

          -  Is fully recovered from any prior major surgery and must be at least 4 weeks
             postoperative

          -  Has Eastern Cooperative Oncology Group Performance Status of 0-2

          -  Has signed a written, voluntary informed consent before study entry, is willing to
             participate in this study, and is willing to complete all follow-up assessments

        Exclusion Criteria:

          -  Has accelerated phase CML as defined by any of the following criteria.

               -  peripheral blood myeloblasts &gt;/=15%

               -  peripheral blood basophils &gt;/= 20%

               -  peripheral blood myeloblasts plus promyelocytes &gt;/=30%

               -  platelets &lt;100,000/microl, unrelated to therapy

          -  Has blastic phase CML (30% myeloblasts in peripheral blood or bone marrow)

          -  Is a candidate for and is planning to receive allogeneic, syngeneic, or autologous
             bone marrow transplantation within the next 12 months

          -  Has received prior treatment for their CML, except for hydroxyurea (collection of stem
             cells without using high dose chemotherapy for mobilization is acceptable)

          -  Has severe cardiovascular disease (i. e., arrhythmias requiring chronic treatment,
             congestive heart failure [New York Heart Association (NYHA) Class III or IV], or
             symptomatic ischemic heart disease)

          -  Has a history of a neuropsychiatric disorder requiring hospitalization

          -  Has thyroid dysfunction not responsive to therapy

          -  Has uncontrolled diabetes mellitus

          -  Has a history of seropositivity for human immunodeficiency virus

          -  Has active and/or uncontrolled infection, including active hepatitis

          -  Has a medical condition requiring chronic systemic corticosteroids

          -  Has a history of prior malignancies within the last 5 years, except for surgically
             cured non-melanoma skin cancer, or cervical carcinoma in situ

          -  Has received any experimental therapy within 30 days prior to enrollment in this study

          -  Is known to be actively abusing alcohol or drugs

          -  Is pregnant, nursing, or of reproductive potential and is not practicing an effective
             means of contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>July 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2019</results_first_posted>
  <last_update_submitted>July 12, 2019</last_update_submitted>
  <last_update_submitted_qc>July 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>INTRON A (Interferon Alfa-2b)</title>
          <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months (mo.) unless there was evidence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>PEG Intron (Pegylated Interferon Alfa-2b)</title>
          <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="171"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
                <participants group_id="P2" count="116"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression/Recurrence</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Therapeutic Response</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Selected</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Continued treatment beyond 12 mo.</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>INTRON A (Interferon Alfa-2b)</title>
          <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>PEG Intron (Pegylated Interferon Alfa-2b)</title>
          <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="173"/>
            <count group_id="B2" value="171"/>
            <count group_id="B3" value="344"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="13.4"/>
                    <measurement group_id="B2" value="51.9" spread="12.8"/>
                    <measurement group_id="B3" value="51.7" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cytogenetic Responses to PEG Intron and INTRON A at 12 Months</title>
        <description>Cytogenetic response (CR) was defined by the degree of suppression of Philadelphia chromosome (Ph^1) achieved during study treatment. For all participants continuing treatment after study conclusion, cytogenetic assessments were conducted locally as per standard of care. Determination of CR at 12 months were based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH^1-positive cells during study treatment. Protocol-defined CR criteria were Complete Response (0%), Partial Response (1-34%), Minor Response (35-90%), or No Response (&gt;90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>All randomized participants analyzed on an intent-to-treat basis.</population>
        <group_list>
          <group group_id="O1">
            <title>INTRON A (Interferon Alfa-2b)</title>
            <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>PEG Intron (Pegylated Interferon Alfa-2b)</title>
            <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cytogenetic Responses to PEG Intron and INTRON A at 12 Months</title>
          <description>Cytogenetic response (CR) was defined by the degree of suppression of Philadelphia chromosome (Ph^1) achieved during study treatment. For all participants continuing treatment after study conclusion, cytogenetic assessments were conducted locally as per standard of care. Determination of CR at 12 months were based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH^1-positive cells during study treatment. Protocol-defined CR criteria were Complete Response (0%), Partial Response (1-34%), Minor Response (35-90%), or No Response (&gt;90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.</description>
          <population>All randomized participants analyzed on an intent-to-treat basis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minor Respnse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Respnse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Discontinued or No Hematologic CR at Month 6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Participants with Missing Data</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.322</p_value>
            <p_value_desc>Analysis of Major Response</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Missing data considered failures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cytogenetic Response (CR) to PEG Intron and Intron A at 6 Months</title>
        <description>Cytogenetic response (CR) at 6 months, as at 12 months, was defined by the degree of suppression of Philadelphia chromosome (Ph^1) achieved during study treatment. The determination of CR at 6 months was based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH^1-positive cells during study treatment. Protocol-defined CR criteria were Complete (0%), Partial (1-34%), Minor (35-90%), or No Response (&gt;90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.</description>
        <time_frame>6 months</time_frame>
        <population>All randomized participants who received at least one dose of assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>INTRON A (Interferon Alfa-2b)</title>
            <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>PEG Intron (Pegylated Interferon Alfa-2b)</title>
            <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cytogenetic Response (CR) to PEG Intron and Intron A at 6 Months</title>
          <description>Cytogenetic response (CR) at 6 months, as at 12 months, was defined by the degree of suppression of Philadelphia chromosome (Ph^1) achieved during study treatment. The determination of CR at 6 months was based on cytogenetic analysis of bone marrow aspirate samples. The CR criteria were based on the percentage (%) of PH^1-positive cells during study treatment. Protocol-defined CR criteria were Complete (0%), Partial (1-34%), Minor (35-90%), or No Response (&gt;90%). Data for the analysis population was based on the intent-to-treat principle. Participants who were treatment failures at 6 months were considered cytogenetic non-responders. Recording of CR was independent of hematologic responses.</description>
          <population>All randomized participants who received at least one dose of assigned treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response: 0% Ph+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response: 1-34% Ph+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor Response: 35-90% Ph+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Response: &gt;90% Ph+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant with Missing Data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <p_value_desc>Analysis of Major Response</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Missing data considered failures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematologic Responses to PEG Intron and Intron A at 6 Months</title>
        <description>Hematologic response at 6 months was assessed, while the hematologic response was measured at 3, 6, 9 and 12 months during the first year of study treatment. To be considered a hematologic responder a participant must have met all of the following criteria for a minimum of 28 days: WBC count &lt;10,000/μL; platelet count &lt;450,000/L; normal differential count in peripheral blood (manual differential count); no palpable spleen. Participants achieving a complete hematologic response at 3 months had the cytogenetic response evaluated at 3 months as well. Participants who achieved a complete hematologic response by 6 months continued treatment for another 6 months. Participants who failed to achieve a complete hematologic response after 6 months of treatment were considered treatment failures, and further treatment for this group was at the discretion of the treating physician. Participants may have continued to receive their assigned study medication for an additional 6 months.</description>
        <time_frame>6 months</time_frame>
        <population>All randomized participants who received at least one dose of assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>INTRON A (Interferon Alfa-2b)</title>
            <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>PEG Intron (Pegylated Interferon Alfa-2b)</title>
            <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematologic Responses to PEG Intron and Intron A at 6 Months</title>
          <description>Hematologic response at 6 months was assessed, while the hematologic response was measured at 3, 6, 9 and 12 months during the first year of study treatment. To be considered a hematologic responder a participant must have met all of the following criteria for a minimum of 28 days: WBC count &lt;10,000/μL; platelet count &lt;450,000/L; normal differential count in peripheral blood (manual differential count); no palpable spleen. Participants achieving a complete hematologic response at 3 months had the cytogenetic response evaluated at 3 months as well. Participants who achieved a complete hematologic response by 6 months continued treatment for another 6 months. Participants who failed to achieve a complete hematologic response after 6 months of treatment were considered treatment failures, and further treatment for this group was at the discretion of the treating physician. Participants may have continued to receive their assigned study medication for an additional 6 months.</description>
          <population>All randomized participants who received at least one dose of assigned treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <p_value_desc>Analysis of Complete Response</p_value_desc>
            <method>Fisher Exact</method>
            <method_desc>Missing data considered failures</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival</title>
        <description>Participants were followed for survival; those who did not achieve a major cytogenetic response were discontinued from the study. For participants who completed 1 year of study treatment and continued to Year 2 and beyond, survival and disease progression every 3 months were assessed, and serious adverse events (SAEs) were reported. Participants were followed until resolution of any drug-related nonserious adverse event, and any SAE occurring while on the study or within 30 days of last dose of study drug. Participant death during survival follow-up was reported to the drug safety unit of the Sponsor. Each participant (whether discontinued or still on treatment) was followed every 3 months for survival and disease progression information. Overall survival was analyzed using the log-rank statistic, and the hazard ratio (HR) and 95% confidence interval (CI) for the HR were obtained using Cox's proportional hazards model.</description>
        <time_frame>Up to 2 years (24 months), and beyond</time_frame>
        <population>All randomized participants who received at least one dose of assigned treatment</population>
        <group_list>
          <group group_id="O1">
            <title>INTRON A (Interferon Alfa-2b)</title>
            <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>PEG Intron (Pegylated Interferon Alfa-2b)</title>
            <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival</title>
          <description>Participants were followed for survival; those who did not achieve a major cytogenetic response were discontinued from the study. For participants who completed 1 year of study treatment and continued to Year 2 and beyond, survival and disease progression every 3 months were assessed, and serious adverse events (SAEs) were reported. Participants were followed until resolution of any drug-related nonserious adverse event, and any SAE occurring while on the study or within 30 days of last dose of study drug. Participant death during survival follow-up was reported to the drug safety unit of the Sponsor. Each participant (whether discontinued or still on treatment) was followed every 3 months for survival and disease progression information. Overall survival was analyzed using the log-rank statistic, and the hazard ratio (HR) and 95% confidence interval (CI) for the HR were obtained using Cox's proportional hazards model.</description>
          <population>All randomized participants who received at least one dose of assigned treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survivors</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.859</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.429</ci_lower_limit>
            <ci_upper_limit>1.721</ci_upper_limit>
            <estimate_desc>Overall survival was analyzed using the log-rank statistic. The HR and 95% CI for the HR were obtained using Cox’s proportional hazards model.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to One Year</time_frame>
      <desc>An AE is any physical or clinical change or disease experienced by the participant at any time during the course of the study, whether or not considered related to the use of the study drug. This includes the onset of new illness and the exacerbation of pre-existing conditions other than the indication under study. The population analyzed was all randomized participants who received at least one dose of study treatment. One randomized participant died before receiving treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>INTRON A, 5 MIU/m^2 Daily</title>
          <description>Interferon alfa-2b, recombinant for injection, 5 million international units (MIU)/m^2, administered daily by SC injection. Treatment was for a minimum of 6 months (mo.) unless there was evidence of disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>PEG-Intron, 6.0 mcg/kg Weekly</title>
          <description>Pegylated interferon alfa-2b, 6.0 microg/kg, administered weekly by subcutaneous (SC) injection. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPERGAMMAGLOBULINAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>OCULAR TOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CYTOLYTIC HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INFECTED CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ABSCESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BODY TEMPERATURE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HEPATITIS B VIRUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LABORATORY TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CELL DEATH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLAST CELL CRISIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BLAST CRISIS IN MYELOGENOUS LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>STATUS EPILEPTICUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="170" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E2" events="43" subjects_affected="21" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="19" subjects_at_risk="173"/>
                <counts group_id="E2" events="38" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="29" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="65" subjects_affected="35" subjects_at_risk="173"/>
                <counts group_id="E2" events="74" subjects_affected="34" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="18" subjects_affected="10" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" events="63" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="36" subjects_affected="22" subjects_at_risk="173"/>
                <counts group_id="E2" events="61" subjects_affected="23" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" events="42" subjects_affected="12" subjects_at_risk="173"/>
                <counts group_id="E2" events="25" subjects_affected="8" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" events="16" subjects_affected="13" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="59" subjects_affected="33" subjects_at_risk="173"/>
                <counts group_id="E2" events="105" subjects_affected="39" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="108" subjects_affected="44" subjects_at_risk="173"/>
                <counts group_id="E2" events="169" subjects_affected="51" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>APHTHOUS STOMATITIS</sub_title>
                <counts group_id="E1" events="15" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="130" subjects_affected="38" subjects_at_risk="173"/>
                <counts group_id="E2" events="89" subjects_affected="36" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="314" subjects_affected="95" subjects_at_risk="173"/>
                <counts group_id="E2" events="503" subjects_affected="104" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="157" subjects_affected="61" subjects_at_risk="173"/>
                <counts group_id="E2" events="179" subjects_affected="57" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="23" subjects_at_risk="173"/>
                <counts group_id="E2" events="33" subjects_affected="18" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="429" subjects_affected="101" subjects_at_risk="173"/>
                <counts group_id="E2" events="627" subjects_affected="111" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ORAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" events="38" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>STOMACH DISCOMFORT</sub_title>
                <counts group_id="E1" events="86" subjects_affected="16" subjects_at_risk="173"/>
                <counts group_id="E2" events="51" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="108" subjects_affected="53" subjects_at_risk="173"/>
                <counts group_id="E2" events="178" subjects_affected="62" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="246" subjects_affected="81" subjects_at_risk="173"/>
                <counts group_id="E2" events="400" subjects_affected="94" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="68" subjects_affected="26" subjects_at_risk="173"/>
                <counts group_id="E2" events="75" subjects_affected="26" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="254" subjects_affected="108" subjects_at_risk="173"/>
                <counts group_id="E2" events="377" subjects_affected="115" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="637" subjects_affected="105" subjects_at_risk="173"/>
                <counts group_id="E2" events="929" subjects_affected="103" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>FEELING COLD</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="24" subjects_affected="6" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" events="25" subjects_affected="12" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" events="22" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E2" events="80" subjects_affected="37" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" events="31" subjects_affected="19" subjects_at_risk="173"/>
                <counts group_id="E2" events="35" subjects_affected="20" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INJECTION SITE RASH</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" events="48" subjects_affected="18" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="34" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E2" events="18" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="45" subjects_affected="19" subjects_at_risk="173"/>
                <counts group_id="E2" events="180" subjects_affected="27" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" events="28" subjects_affected="18" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="135" subjects_affected="49" subjects_at_risk="173"/>
                <counts group_id="E2" events="236" subjects_affected="48" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="468" subjects_affected="133" subjects_at_risk="173"/>
                <counts group_id="E2" events="1121" subjects_affected="141" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>THIRST</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="173"/>
                <counts group_id="E2" events="56" subjects_affected="24" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" events="17" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="128" subjects_affected="69" subjects_at_risk="173"/>
                <counts group_id="E2" events="122" subjects_affected="81" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" events="39" subjects_affected="12" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="218" subjects_affected="86" subjects_at_risk="173"/>
                <counts group_id="E2" events="315" subjects_affected="103" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="52" subjects_affected="24" subjects_at_risk="173"/>
                <counts group_id="E2" events="63" subjects_affected="29" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="401" subjects_affected="79" subjects_at_risk="173"/>
                <counts group_id="E2" events="474" subjects_affected="87" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="337" subjects_affected="82" subjects_at_risk="173"/>
                <counts group_id="E2" events="472" subjects_affected="80" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="93" subjects_affected="24" subjects_at_risk="173"/>
                <counts group_id="E2" events="292" subjects_affected="48" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="30" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="54" subjects_affected="21" subjects_at_risk="173"/>
                <counts group_id="E2" events="69" subjects_affected="14" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="25" subjects_affected="16" subjects_at_risk="173"/>
                <counts group_id="E2" events="36" subjects_affected="17" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="34" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="89" subjects_affected="38" subjects_at_risk="173"/>
                <counts group_id="E2" events="65" subjects_affected="33" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E2" events="51" subjects_affected="16" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="416" subjects_affected="109" subjects_at_risk="173"/>
                <counts group_id="E2" events="532" subjects_affected="99" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="28" subjects_affected="16" subjects_at_risk="173"/>
                <counts group_id="E2" events="51" subjects_affected="17" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="304" subjects_affected="64" subjects_at_risk="173"/>
                <counts group_id="E2" events="187" subjects_affected="56" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AGEUSIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>AMNESIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DISTURBANCE IN ATTENTION</sub_title>
                <counts group_id="E1" events="27" subjects_affected="12" subjects_at_risk="173"/>
                <counts group_id="E2" events="15" subjects_affected="9" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="256" subjects_affected="68" subjects_at_risk="173"/>
                <counts group_id="E2" events="252" subjects_affected="59" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="75" subjects_affected="34" subjects_at_risk="173"/>
                <counts group_id="E2" events="101" subjects_affected="35" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="716" subjects_affected="128" subjects_at_risk="173"/>
                <counts group_id="E2" events="1362" subjects_affected="132" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E2" events="43" subjects_affected="24" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E2" events="34" subjects_affected="22" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" events="32" subjects_affected="10" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="44" subjects_affected="24" subjects_at_risk="173"/>
                <counts group_id="E2" events="59" subjects_affected="20" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="44" subjects_affected="20" subjects_at_risk="173"/>
                <counts group_id="E2" events="55" subjects_affected="23" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="61" subjects_affected="33" subjects_at_risk="173"/>
                <counts group_id="E2" events="110" subjects_affected="42" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DEPRESSED MOOD</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="22" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="111" subjects_affected="51" subjects_at_risk="173"/>
                <counts group_id="E2" events="131" subjects_affected="58" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="128" subjects_affected="57" subjects_at_risk="173"/>
                <counts group_id="E2" events="150" subjects_affected="48" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="122" subjects_affected="69" subjects_at_risk="173"/>
                <counts group_id="E2" events="120" subjects_affected="56" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="98" subjects_affected="37" subjects_at_risk="173"/>
                <counts group_id="E2" events="89" subjects_affected="38" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="173"/>
                <counts group_id="E2" events="37" subjects_affected="22" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" events="13" subjects_affected="7" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="101" subjects_affected="36" subjects_at_risk="173"/>
                <counts group_id="E2" events="109" subjects_affected="44" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="36" subjects_affected="19" subjects_at_risk="173"/>
                <counts group_id="E2" events="30" subjects_affected="20" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E2" events="37" subjects_affected="20" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="84" subjects_affected="67" subjects_at_risk="173"/>
                <counts group_id="E2" events="70" subjects_affected="53" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="48" subjects_affected="24" subjects_at_risk="173"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="55" subjects_affected="36" subjects_at_risk="173"/>
                <counts group_id="E2" events="121" subjects_affected="42" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" events="49" subjects_affected="21" subjects_at_risk="173"/>
                <counts group_id="E2" events="73" subjects_affected="30" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="97" subjects_affected="37" subjects_at_risk="173"/>
                <counts group_id="E2" events="57" subjects_affected="30" subjects_at_risk="171"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="46" subjects_affected="27" subjects_at_risk="173"/>
                <counts group_id="E2" events="56" subjects_affected="23" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" events="20" subjects_affected="14" subjects_at_risk="171"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators have the right to publish or publicly present the results of the study. Principal Investigators further agree to provide to the Sponsor thirty (30) days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication. No publication or manuscript shall contain any trade secret information of the Sponsor or any proprietary or confidential information of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>AE Preferred Terms were converted from WHO-ART dictionary to the MedDRA version 10.0</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

